| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection MW Fried, ML Shiffman, KR Reddy, C Smith, G Marinos, FL Gonçales Jr, ... New England journal of medicine 347 (13), 975-982, 2002 | 8664 | 2002 |
| Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various … Antiplatelet Trialists' Collaboration Bmj 308 (6921), 81-106, 1994 | 5053 | 1994 |
| The effect of digoxin on mortality and morbidity in patients with heart failure Digitalis Investigation Group New England Journal of Medicine 336 (8), 525-533, 1997 | 3643 | 1997 |
| Boceprevir for untreated chronic HCV genotype 1 infection F Poordad, J McCone Jr, BR Bacon, S Bruno, MP Manns, MS Sulkowski, ... New England Journal of Medicine 364 (13), 1195-1206, 2011 | 3384 | 2011 |
| Telaprevir for previously untreated chronic hepatitis C virus infection IM Jacobson, JG McHutchison, G Dusheiko, AM Di Bisceglie, KR Reddy, ... New England Journal of Medicine 364 (25), 2405-2416, 2011 | 3286 | 2011 |
| Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection A Regev, M Berho, LJ Jeffers, C Milikowski, EG Molina, NT Pyrsopoulos, ... The American journal of gastroenterology 97 (10), 2614-2618, 2002 | 2594 | 2002 |
| Sofosbuvir for previously untreated chronic hepatitis C infection E Lawitz, A Mangia, D Wyles, M Rodriguez-Torres, T Hassanein, ... New England Journal of Medicine 368 (20), 1878-1887, 2013 | 2429 | 2013 |
| Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Afdhal, KR Reddy, DR Nelson, E Lawitz, SC Gordon, E Schiff, ... New England Journal of Medicine 370 (16), 1483-1493, 2014 | 1720 | 2014 |
| Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection MS Sulkowski, DF Gardiner, M Rodriguez-Torres, KR Reddy, ... New England Journal of Medicine 370 (3), 211-221, 2014 | 1565 | 2014 |
| Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis KV Kowdley, SC Gordon, KR Reddy, L Rossaro, DE Bernstein, E Lawitz, ... New England Journal of Medicine 370 (20), 1879-1888, 2014 | 1510 | 2014 |
| Diagnosis and treatment of hepatocellular carcinoma HB El-Serag, JA Marrero, L Rudolph, KR Reddy Gastroenterology 134 (6), 1752-1763, 2008 | 1340 | 2008 |
| ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury NP Chalasani, PH Hayashi, HL Bonkovsky, VJ Navarro, WM Lee, ... Official journal of the American College of Gastroenterology| ACG 109 (7 …, 2014 | 1248* | 2014 |
| ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV P Ferenci, D Bernstein, J Lalezari, D Cohen, Y Luo, C Cooper, E Tam, ... New England Journal of Medicine 370 (21), 1983-1992, 2014 | 1002 | 2014 |
| Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis MP Curry, JG O’Leary, N Bzowej, AJ Muir, KM Korenblat, JM Fenkel, ... New England Journal of Medicine 373 (27), 2618-2628, 2015 | 961 | 2015 |
| Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease M Charlton, GT Everson, SL Flamm, P Kumar, C Landis, RS Brown Jr, ... Gastroenterology 149 (3), 649-659, 2015 | 950 | 2015 |
| α-fetoprotein, des-γ carboxyprothrombin, and lectin-bound α-fetoprotein in early hepatocellular carcinoma JA Marrero, Z Feng, Y Wang, MH Nguyen, AS Befeler, LR Roberts, ... Gastroenterology 137 (1), 110-118, 2009 | 874 | 2009 |
| Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study N Chalasani, HL Bonkovsky, R Fontana, W Lee, A Stolz, J Talwalkar, ... Gastroenterology 148 (7), 1340-1352. e7, 2015 | 825 | 2015 |
| Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial S Zeuzem, R Ghalib, KR Reddy, PJ Pockros, ZB Ari, Y Zhao, DD Brown, ... Annals of internal medicine 163 (1), 1-13, 2015 | 682 | 2015 |
| Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin P Ferenci, MW Fried, ML Shiffman, CI Smith, G Marinos, FL Gonçales Jr, ... Journal of hepatology 43 (3), 425-433, 2005 | 674 | 2005 |
| Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α‐2a (40 kd)/ribavirin therapy DM Jensen, TR Morgan, P Marcellin, PJ Pockros, KR Reddy, ... Hepatology 43 (5), 954-960, 2006 | 664 | 2006 |
Jasmohan BajajVirginia Commonwealth University and McGuire VA Medical Center在 vcu.edu 的电子邮件经过验证
